Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

← catalyst calendar

NCT04159103 · readout in 377 d

Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

77estimated

Sites

Countries

Canada, France, Japan +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-04-15

actual

When the study began enrolling

Primary completion

2027-08-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-08-31

estimated

The whole study's end, after follow-up

First posted

2019-11-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Propionic Acidemia

Intervention

Biological: mRNA-3927

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Number of Participants with Treatment-emergent Adverse Event (TEAE), Serious Adverse Events (SAE) and TEAEs Leading to Discontinuation

measured Day 1 (initial mRNA-3927 dose) up to Week 150 (End of Study)

Part 2: Change in Annualized Frequency of Clinical Event Committee (CEC)-adjudicated Metabolic Decompensation Events (MDEs) During 12-month Treatment Period With mRNA-3927 Compared to Annualized Frequency of CEC-adjudicated MDE During Pretreatment Period

measured Pretreatment period (12 months before consent to first mRNA-3927 dose in the study) up to Month 12

Part 3: Number of Participants with TEAEs, SAEs, Adverse Events (AEs) of Special Interest (AESIs) and TEAEs Leading to Discontinuation

measured Day 1 up to Week 73

Publications

PMID 36577040 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed